The United States Food and Drug Administration (USFDA) has conducted a routine current Good Manufacturing Practices (cGMP) inspection at Wanbury’s facility at Tanuku, West Godavari District, Andhra Pradesh during the period from July 13, 2026 to July 17, 2026.
At the conclusion of the inspection, the USFDA has issued a Form 483 with six observations. The company will respond to these observations to FDA within the stipulated time.
Wanbury, one of India’s fastest growing pharmaceutical companies amongst the ‘Top 50 Companies’ in India (as per ORG-IMS), has a strong presence in API global market and domestic branded Formulation.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1962.15 |
| Dr. Reddys Labs. | 1206.55 |
| Cipla | 1432.55 |
| Lupin | 2514.40 |
| Zydus Lifesciences | 1143.65 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: